CoChat

Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells

Open access
Burkhardt, Ute E., Hainz, Ursula, Stevenson, Kristen, Goldstein, Natalie R., Pasek, Mildred, Naito, Masayasu, Wu, Di, Ho, Vincent T., Alonso, Anselmo, Hammond, Naa Norkor, Wong, Jessica, Sievers, Quinlan L., Brusic, Ana, McDonough, Sean M., Zeng, Wanyong, Perrin, Ann, Brown, Jennifer R., Canning, Christine M., Koreth, John, Cutler, Corey, Armand, Philippe, Neuberg, Donna, Lee, Jeng-Shin, Antin, Joseph H., Mulligan, Richard C., Sasada, Tetsuro, Ritz, Jerome, Soiffer, Robert J., Dranoff, Glenn, Alyea, Edwin P., Wu, Catherine J. · 2013 · Journal of Clinical Investigation
Cited by 79

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Patients with advanced hematologic malignancies remain at risk for relapse following reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (allo-HSCT). We conducted a prospective clinical trial to test whether vaccination with whole leukemia cells early after transplantation facilitates the expansion of leukemia-reactive T cells and thereby enhances antitumor immunity. METHODS: We enrolled 22 patients with advanced chronic lymphocytic leukemia (CLL), 18 of whom received up to 6 vaccines initiated between days 30 and 45 after transplantation. Each vaccine consisted of irradiated autologous tumor cells admixed with GM-CSF-secreting bystander cells. Serial patient PBMC samples following transplantation were collected, and the impact of vaccination on T cell activity was evaluated. RESULTS: At a median follow-up of 2.9 (range, 1-4) years, the estimated 2-year progression-free and overall survival rates of vaccinated subjects were 82% (95% CI, 54%-94%) and 88% (95% CI, 59%-97%), respectively. Although vaccination only had a modest impact on recovering T cell numbers, CD8+ T cells from vaccinated patients consistently reacted against autologous tumor, but not alloantigen-bearing recipient cells with increased secretion of the effector cytokine IFN-γ, unlike T cells from nonvaccinated CLL patients undergoing allo-HSCT. Further analysis confirmed that 17% (range, 13%-33%) of CD8+ T cell clones isolated from 4 vaccinated patients by limiting dilution of bulk tumor-reactive T cells solely reacted against CLL-associated antigens. CONCLUSION: Our studies suggest that autologous tumor cell vaccination is an effective strategy to advance long-term leukemia control following allo-HSCT. TRIAL REGISTRATION: Clinicaltrials.gov NCT00442130. FUNDING: NCI (5R21CA115043-2), NHLBI (5R01HL103532-03), and Leukemia and Lymphoma Society Translational Research Program.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci69098

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 79

Metadata

Authors
Burkhardt, U. E., Hainz, U., Stevenson, K., Goldstein, N. R., Pasek, M., Naito, M., Wu, D., Ho, V. T., Alonso, A., Hammond, N. N., Wong, J., Sievers, Q. L., Brusic, A., McDonough, S. M., Zeng, W., Perrin, A., Brown, J. R., Canning, C. M., Koreth, J., Cutler, C., Armand, P., Neuberg, D., Lee, J.-S., Antin, J. H., Mulligan, R. C., Sasada, T., Ritz, J., Soiffer, R. J., Dranoff, G., Alyea, E. P., & Wu, C. J.
Venue
Journal of Clinical Investigation
Published
2013-08-05
Volume
123
Issue
9
Pages
3756-3765
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2155918010
Cited by
79
References
1
FWCI
5.82
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.